AZN - AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion
On Saturday morning, AstraZeneca (NASDAQ: AZN) announced an agreement to buy Alexion Pharmaceuticals (NASDAQ: ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. Based on AstraZeneca's closing price on Friday, Alexion shareholders are in line to receive about $175 per share.
Regulatory hurdles that come with big international mergers are expected to keep this one from completing until the third quarter of 2021. Based on yesterday's closing prices for both stocks, though, AstraZeneca's offer represents a 45% premium.
Image source: Getty Images.
For further details see:
AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion